Dora Hatzidaki

55 Lombardou St
Athens, ESYE31 11474, Greece

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Prognostic and Predictive Value of Peripheral CD8/PD-1/TCF-1 Positive T Cells in Non-Small Cell Lung Carcinoma Patients.

Prognostic and Predictive Value of Peripheral CD8/PD-1/TCF-1 Positive T Cells in Non-Small Cell Lung Carcinoma Patients.

Journal: ImmunoTargets and therapy
Published: January 10, 2026

Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.

Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.

Journal: BMJ oncology
Published: March 14, 2025

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer.

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer.

Journal: NPJ precision oncology
Published: July 10, 2024

LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer.

LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer.

Journal: Cancers
Published: April 07, 2024

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.

Journal: Cancers
Published: July 18, 2023

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.

Journal: Cancers
Published: January 31, 2022

Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group.

Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group.

Journal: Current oncology (Toronto, Ont.)
Published: December 07, 2021

Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period.

Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period.

Journal: Breast care (Basel, Switzerland)
Published: July 28, 2021

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.

Journal: British journal of cancer
Published: July 24, 2021

Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.

Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.

Journal: Cancer chemotherapy and pharmacology
Published: September 19, 2020

Chemotherapy use near the end-of-life in patients with metastatic breast cancer.

Chemotherapy use near the end-of-life in patients with metastatic breast cancer.

Journal: Breast cancer research and treatment
Published: March 30, 2020

MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.

MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.

Journal: Targeted oncology
Published: June 17, 2019
Showing 1-12 of 32

Last Updated: 09/26/2026